Literature DB >> 2739578

Regulation of plasma growth hormone-binding proteins in health and disease.

G Baumann1, M A Shaw, K Amburn.   

Abstract

Binding proteins (BP) for growth hormone (GH) have recently been discovered in human plasma. The main BP is related to the GH receptor and probably corresponds to the extracellular portion of the receptor. The BP influence several aspects of GH homeostasis and action. Their level and activity in blood, therefore, become important variables in overall GH physiology. However, to date little is known about the regulation of GH-BP in health and disease. To gain initial information about this point, GH-BP activity was examined in the plasma of 124 subjects with various physiologic and pathologic conditions. The conditions were selected to provide basic physiologic data (men, women, children, age, pregnancy and to investigate key disease states attended by abnormal GH physiology (liver cirrhosis, uremia, infection, acromegaly). A standardized GH binding assay was used to measure BP activity as an index of BP levels. Both the principal, high affinity BP (peak II) and the minor, low affinity BP (peak I) showed considerable individual variation in all groups. Neonates had the lowest levels of both BPs, but by the age of 1 year the levels had increased and remained fairly stable through the seventh decade. In males but not females between the ages of 1 and 20 years, the main (peak II) BP showed a slight upward trend, whereas the minor (peak I) BP declined moderately. Patients with cirrhosis showed the most variation in both BP, and uremic patients demonstrated decreased peak II, but not peak I, binding. Neither BP was affected in acromegaly. We conclude that BP activity in plasma is well conserved in most conditions, but substantial individual variability exists. BP activity increases dramatically during the first year of life.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2739578     DOI: 10.1016/0026-0495(89)90108-x

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

Review 1.  The relevance of pharmacokinetics in the development of biotechnology products.

Authors:  S Toon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 2.  Disturbance of growth hormone--insulin-like growth factor axis in uraemia. Implications for recombinant human growth hormone treatment.

Authors:  B Tönshoff; F Schaefer; O Mehls
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

3.  A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse).

Authors:  Y Zhou; B C Xu; H G Maheshwari; L He; M Reed; M Lozykowski; S Okada; L Cataldo; K Coschigamo; T E Wagner; G Baumann; J J Kopchick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 4.  Circulating growth hormone binding proteins.

Authors:  G Baumann; M A Shaw; K Amburn
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

5.  Growth responses to patterned GH delivery.

Authors:  R G Clark; D Mortensen; L M Carlsson; D Carmignac; I Robinson
Journal:  Endocrine       Date:  1995-10       Impact factor: 3.633

6.  Liver-derived IGF-I contributes to GH-dependent increases in lean mass and bone mineral density in mice with comparable levels of circulating GH.

Authors:  Sarah M Nordstrom; Jennifer L Tran; Brandon C Sos; Kay-Uwe Wagner; Ethan J Weiss
Journal:  Mol Endocrinol       Date:  2011-04-28

Review 7.  Growth hormone/insulin-like growth factor system in children with chronic renal failure.

Authors:  Burkhard Tönshoff; Daniela Kiepe; Sonia Ciarmatori
Journal:  Pediatr Nephrol       Date:  2005-02-04       Impact factor: 3.714

8.  Serum growth hormone-binding protein is decreased in prepubertal children with idiopathic short stature.

Authors:  N Dávila; M Moreira-Andrés; J Alcañiz; B Barceló
Journal:  J Endocrinol Invest       Date:  1996-06       Impact factor: 4.256

9.  Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications.

Authors:  J D Veldhuis; M L Johnson; L M Faunt; M Mercado; G Baumann
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

Review 10.  Growth hormone binding protein and free growth hormone in chronic renal failure.

Authors:  G Baumann
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.